A team led by researchers at the Science for Life Laboratory Stockholm has linked the nuclear receptor protein retinoic acid receptor alpha to tamoxifen resistance in breast cancer.

According to Janne Lehtiö, platform manager for mass spectrometry at SciLifeLab and leader of the effort, the findings suggest that RARA could serve as a biomarker for predicting patient response to tamoxifen treatment as well as a therapeutic target.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.